+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Xeljanz"

Rheumatoid Arthritis Market and Forecast Analysis to 2025 - Product Thumbnail Image

Rheumatoid Arthritis Market and Forecast Analysis to 2025

  • Drug Pipelines
  • August 2018
  • 610 Pages
  • Global
From
Psoriatic Arthritis Market and Forecast Analysis 2035 - Product Thumbnail Image

Psoriatic Arthritis Market and Forecast Analysis 2035

  • Drug Pipelines
  • July 2018
  • 503 Pages
  • Global
From
Loading Indicator

Xeljanz (tofacitinib) is a drug used to treat immune disorders, such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It is a Janus kinase (JAK) inhibitor, which works by blocking certain proteins that are involved in the body's inflammatory response. Xeljanz is taken orally, usually twice daily, and is available in both tablet and suspension form. It is typically used in combination with other medications, such as methotrexate or biologic drugs. Xeljanz is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2012. It has become a popular treatment option for immune disorders, due to its effectiveness and convenience. Companies in the Xeljanz market include Pfizer, which manufactures and markets the drug, as well as other pharmaceutical companies that produce generic versions of the drug. Additionally, there are numerous companies that provide support services, such as patient assistance programs and educational materials. Show Less Read more